Literature DB >> 1555635

Antiarrhythmic effects of U-50,488H in rats subject to coronary artery occlusion.

M K Pugsley1, W P Penz, M J Walker, T M Wong.   

Abstract

The antiarrhythmic actions of low and high doses of U-50,488H, a selective kappa-receptor agonist, were examined in pentobarbitone-anaesthetized rats subjected to occlusion of the left anterior descending coronary artery. At a high dose (16 mumol/kg) U-50,488H reduced blood pressure, heart rate and prolonged the P-R and QRS intervals of the electrocardiogram. This dose reduced the incidence of ventricular arrhythmias produced by occlusion. The blood pressure, heart rate, ECG and antiarrhythmic actions of a high dose of U-50,488H were not antagonized by 8 mumol/kg naloxone, a dose which had no cardiovascular or ECG actions. Naloxone alone reduced arrhythmia incidence but to a lesser extent than U-50,488H. A low dose (0.2 mumol/kg) of U50,488H in the absence or presence of naloxone had no effect on arrhythmias. Thus, U-50,488H had antiarrhythmic actions at a high dose which were independent of opioid receptors.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1555635     DOI: 10.1016/0014-2999(92)90066-d

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  6 in total

Review 1.  Opioid-induced cardioprotection.

Authors:  Katsuya Tanaka; Judy R Kersten; Matthias L Riess
Journal:  Curr Pharm Des       Date:  2014       Impact factor: 3.116

2.  Molecular analysis of the Na+ channel blocking actions of the novel class I anti-arrhythmic agent RSD 921.

Authors:  M K Pugsley; A L Goldin
Journal:  Br J Pharmacol       Date:  1999-05       Impact factor: 8.739

3.  Electrophysiological and antiarrhythmic actions of the kappa agonist PD 129290, and its R,R (+)-enantiomer, PD 129289.

Authors:  M K Pugsley; D A Saint; M P Penz; M J Walker
Journal:  Br J Pharmacol       Date:  1993-12       Impact factor: 8.739

Review 4.  Prospects for Creation of Cardioprotective and Antiarrhythmic Drugs Based on Opioid Receptor Agonists.

Authors:  Leonid N Maslov; Igor Khaliulin; Peter R Oeltgen; Natalia V Naryzhnaya; Jian-Ming Pei; Stephen A Brown; Yury B Lishmanov; James M Downey
Journal:  Med Res Rev       Date:  2016-05-16       Impact factor: 12.944

5.  κ-opioid receptor is involved in the cardioprotection induced by exercise training.

Authors:  Xiao Geng; Honglin Zhao; Shumiao Zhang; Juan Li; Fei Tian; Na Feng; Rong Fan; Min Jia; Haitao Guo; Liang Cheng; Jincheng Liu; Wensheng Chen; Jianming Pei
Journal:  PLoS One       Date:  2017-03-16       Impact factor: 3.240

6.  Impact of Morphine Treatment on Infarct Size and Reperfusion Injury in Acute Reperfused ST-Elevation Myocardial Infarction.

Authors:  Ingo Eitel; Juan Wang; Thomas Stiermaier; Georg Fuernau; Hans-Josef Feistritzer; Alexander Joost; Alexander Jobs; Moritz Meusel; Christian Blodau; Steffen Desch; Suzanne de Waha-Thiele; Harald Langer; Holger Thiele
Journal:  J Clin Med       Date:  2020-03-09       Impact factor: 4.241

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.